Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants

Show simple item record Van Rijn, Piet A. Maris-Veldhuis, Mieke A. Grobler, Maria Jacoba Wright, Isabel M. Erasmus, Baltus J. Maartens, Louis H. Potgieter, Christiaan A. 2021-09-30T13:56:27Z 2021-09-30T13:56:27Z 2020-10
dc.description.abstract African horse sickness virus (AHSV) is a virus species in the genus Orbivirus of the family Reoviridae causing African Horse Sickness (AHS) in equids with a mortality of about 95% in naïve horses. AHS causes serious losses in developing countries where horses play a central role in draft power and transportation. There are nine AHSV serotypes inducing no or low cross-neutralizing antibodies. AHSV is spread by biting Culicoides midges. AHS is endemic in sub-Saharan Africa, and a serious threat outside Africa, since Culicoides species in moderate climate conditions are spreading the closely related bluetongue virus. AHS outbreaks will be devastating for the equestrian industry in developed countries. Live-attenuated vaccines (LAVs) are licensed, marketed and in use in Africa. Their application is controversial with regard to safety issues. LAVs are not allowed in AHS-free countries. We here studied inactivated AHSV with different adjuvants in guinea pigs and horses. Subcutaneous and intramuscular vaccination were studied in horses. Local reactions were observed after prime and boost vaccination. In general, neutralizing antibodies (nAbs) titres were very low after prime vaccination, whereas boost vaccination resulted in high nAb titres for some adjuvants. Vaccinated horses were selected based on local reactions and nAb titres to study efficacy. Unfortunately, not all vaccinated horses survived virulent AHSV infection. Further, most survivors temporarily developed clinical signs and viremia. Further, the current prototype inactivated AHS vaccine is not suitable as emergency vaccine, because onset of protection is slow and requires boost vaccinations. On the other hand, inactivated AHS vaccine is completely safe with respect to virus spread, and incorporation of the DIVA principle based on NS3/NS3a serology and exploring a vaccine production platform for other serotypes is feasible. A superior adjuvant increasing the protective response without causing local reactions will be required to develop payable and acceptable inactivated AHS vaccines. en_ZA
dc.description.department Production Animal Studies en_ZA
dc.description.librarian am2021 en_ZA
dc.description.sponsorship The Dutch Ministry of Agriculture, Nature and Food Quality en_ZA
dc.description.uri en_ZA
dc.identifier.citation Van Rijn, P.A., Maris-Veldhuis, M.A., Grobler, M. et al. 2020, 'Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants', Vaccine, vol. 38, pp. 7108-7117. en_ZA
dc.identifier.issn 0264-410X (print)
dc.identifier.issn 1873-2518 (online)
dc.identifier.other 10.1016/j.vaccine.2020.08.072
dc.language.iso en en_ZA
dc.publisher Elsevier en_ZA
dc.rights © 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license. en_ZA
dc.subject Inactivated vaccine en_ZA
dc.subject Adjuvant en_ZA
dc.subject African horse sickness virus (AHSV) en_ZA
dc.subject African horse sickness (AHS) en_ZA
dc.title Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants en_ZA
dc.type Article en_ZA

Files in this item

This item appears in the following Collection(s)

Show simple item record